Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
← catalyst calendarNCT07531095 · readout in 641 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
160estimated
Sites
24
Countries
Belgium, France, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-21 | actual | When the study began enrolling |
| Primary completion | 2028-05-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-05-21 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Cancer
Interventions
- Drug: ZL-1310
- Drug: Tarlatamab — also filed as IMDELLTRA
- Drug: Durvalumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
measured Up to 3.5 years
Parts 1 and 3: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
measured Up to Day 21
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed